As of today (2024-05-16), Inhibrx's share price is $34.37. Inhibrx's Tangible Book per Share of Mar. 2024 for the quarter that ended in Mar. 2024 was $0.24. Hence, Inhibrx's Price to Tangible Book Ratio of today is 146.26.
The historical rank and industry rank for Inhibrx's Price-to-Tangible-Book or its related term are showing as below:
INBX'
s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 6.7 Med: 27.64 Max: 148.77
Current: 143.21
During the past 7 years, Inhibrx's highest Price to Tangible Book Ratio was 148.77. The lowest was 6.70. And the median was 27.64.
INBX's Price-to-Tangible-Book is ranked worse than 99.43% of 1231
companies
in the Biotechnology industry
Industry Median: 2.81
vs INBX: 143.21
A closely related ratio is called PB Ratio. As of today, Inhibrx's share price is $34.37. Inhibrx's Book Value per Sharefor the quarter that ended in Mar. 2024 was $0.24. Hence, Inhibrx's P/B Ratio of today is 146.26.
Inhibrx Price-to-Tangible-Book Historical Data
The historical data trend for Inhibrx's Price-to-Tangible-Book can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Inhibrx's Price-to-Tangible-Book
For the Biotechnology subindustry, Inhibrx's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Inhibrx's Price-to-Tangible-Book Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Inhibrx's Price-to-Tangible-Book distribution charts can be found below:
* The bar in red indicates where Inhibrx's Price-to-Tangible-Book falls into.
Inhibrx Price-to-Tangible-Book Calculation
Inhibrx's price-to-tangible-book ratio for today is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.
Inhibrx Price-to-Tangible-Book Related Terms
Thank you for viewing the detailed overview of Inhibrx's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.
Inhibrx Inc is a clinical-stage biotechnology company focused on developing a pipeline of novel biologic therapeutic candidates. It combines an understanding of target biology with protein engineering, proprietary discovery technologies, and an integrative approach to research and development to design differentiated therapeutic candidates. The company has four programs in clinical trials, of which three of the programs are for the treatment of various cancers, and one for the treatment of Alpha-1 Antitrypsin Deficiency.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
INBX has been successfully added to your 